Cleveland BioLabs

EOSERA Announces Three EmpowHERment Pitch Finalists; One Woman-Led Company Will Win $10K

Retrieved on: 
Thursday, October 20, 2022

FORT WORTH, Texas, Oct. 20, 2022 /PRNewswire/ -- Boozy Bites, Heralogie, and PWR WMN have been selected finalists and will compete for the $10k prize in EOSERA® INC.'s inaugural EmpowHERment Pitch Competition. Elyse Stoltz Dickerson, CEO of the Fort Worth-based success story got an early jump start by winning a pitch competition and is giving these three smart, innovative, woman-led, Texas-based companies a similar opportunity. 

Key Points: 
  • FORT WORTH, Texas, Oct. 20, 2022 /PRNewswire/ -- Boozy Bites, Heralogie, and PWR WMN have been selected finalists and will compete for the $10k prize in EOSERA INC.'s inaugural EmpowHERment Pitch Competition.
  • The EmpowHERment Pitch Competition will be an annual competition held during Global Entrepreneurship Week every November.
  • When EOSERA won their pitch competition, it propelled our company forward and took us to the next level.
  • EOSERA, Inc. is a biotech company that develops innovative products that target under addressed healthcare needs in the ear care space.

Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing

Retrieved on: 
Monday, May 23, 2022

In addition, the Company has the potential to reinvirogate its pipeline with certain assets from Lay Sciences, Inc. as previously announced.

Key Points: 
  • In addition, the Company has the potential to reinvirogate its pipeline with certain assets from Lay Sciences, Inc. as previously announced.
  • On April 19, 2022, the Company received notification from Nasdaq that it had failed to comply with Nasdaq Listing Rule 5250(c)(1) because it was delinquent in filing its Annual Report on Form 10-K for the period ending December 31, 2021.
  • In a subsequent letter dated May 18, 2022 the Company received further notification from Nasdaq that it had failed to comply with Nasdaq Listing Rule 5250(c)(1) because it was delinquent in filing its Quarterly Report on Form 10-Q for the three-month period ending March 31, 2022.
  • Statera has clinicalprograms for Crohns disease (STAT-201),hematology (Entolimod), pancreatic cancer (STAT-401) andCOVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.To learn more about Statera Biopharma, please visit www.staterabiopharma.com .

Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products

Retrieved on: 
Friday, May 13, 2022

The strategic partnership with Lay Sciences has the potential to produce near term revenue, said Michael K. Handley, President and Chief Executive Officer of Statera Biopharma.

Key Points: 
  • The strategic partnership with Lay Sciences has the potential to produce near term revenue, said Michael K. Handley, President and Chief Executive Officer of Statera Biopharma.
  • Statera also receives the right to license and commercialize current and future products for other indications.
  • Using patent pending and proprietary technologies owned by Lay Sciences or licensed from its partnering companies, ReaGene Biosciences Pvt.
  • Ltd., Lay Sciences is dedicated to developing and providing innovative products and devices focused on treating and preventing diseases of the GI tract.

Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone

Retrieved on: 
Wednesday, April 27, 2022

The transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a contingency on Immune Therapeutics financing.

Key Points: 
  • The transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a contingency on Immune Therapeutics financing.
  • Under the anticipated terms of the agreement, Statera will receive an initial $2 million upfront payment and 5% of the issued and outstanding stock of Immune Therapeutics.
  • Stateras naltrexone assets will be a great addition to our immune-modulation products and immunotherapy technologies, said Kevin Phelps, CEO, Immune Therapeutics.
  • The companys technology platform is built on two different immunotherapies, Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK).

Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-K Filing

Retrieved on: 
Friday, April 22, 2022

There is no assurance, however, that the Companys plan will be accepted by Nasdaq nor that the Company will successfully implement its plan.

Key Points: 
  • There is no assurance, however, that the Companys plan will be accepted by Nasdaq nor that the Company will successfully implement its plan.
  • Further on April 13, 2022, the Company announced it was no longer in compliance with several of the Nasdaq Stock Markets rules.
  • First, under Nasdaq Listing Rule 5605(b)(1), a majority of the directors on the Board must be independent directors, as defined under the Nasdaq rules.
  • If Nasdaq accepts the plan, Nasdaq can grant an extension of up to 180 calendar days from April 4, 2022, the date of Nasdaqs letter to the Company regarding this noncompliance matter, to evidence compliance.

Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod

Retrieved on: 
Wednesday, April 13, 2022

Coeptis commitment to cancer therapies makes it a natural choice for the further development of Entolimod, which has demonstrated potential in multiple preclinical disease models, said Michael K. Handley, President and Chief Executive Officer of Statera Biopharma.

Key Points: 
  • Coeptis commitment to cancer therapies makes it a natural choice for the further development of Entolimod, which has demonstrated potential in multiple preclinical disease models, said Michael K. Handley, President and Chief Executive Officer of Statera Biopharma.
  • Under the terms of the definitive agreement, Statera will receive a $6 million upfront payment and revenue-based milestone payments from Coeptis in exchange for Stateras rights to any product containing Entolimod as an active ingredient and all other related TLR5 agonists.
  • We are excited to undertake this strategic investment to help develop innovative therapeutics that offer improved patient outcomes, said Dave Mehalick, Chairman, President and Chief Executive Officer of Coeptis.
  • Statera has clinicalprograms for Crohns disease (STAT-201),hematology (Entolimod), pancreatic cancer (STAT-401) andCOVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.To learn more about Statera Biopharma, please visit www.staterabiopharma.com .

Statera Biopharma Submits Phase 3 Clinical Trial Protocol to FDA for Investigational Treatment of Pediatric Crohn’s Disease

Retrieved on: 
Wednesday, December 29, 2021

Submitting our Phase 3 clinical trial protocol is a critical milestone in our development program, said Michael K. Handley, President and Chief Executive Officer, Statera Biopharma.

Key Points: 
  • Submitting our Phase 3 clinical trial protocol is a critical milestone in our development program, said Michael K. Handley, President and Chief Executive Officer, Statera Biopharma.
  • In addition to the common GI symptoms, children with Crohns Disease often experience growth failure, malnutrition, delayed puberty, and bone demineralization.
  • STAT-201 has the potential to provide great physical and emotional relief to adolescents who live with Crohns Disease.
  • The trial sites are currently being selected and enrollment is expected to launch in early 2022.

K2bio Welcomes Ponce Therapeutics to Houston

Retrieved on: 
Wednesday, December 22, 2021

HOUSTON, Dec. 21, 2021 /PRNewswire/ -- Ponce Therapeutics, founded by former Bellicum leaders Kevin Slawin and David Spencer, have signed an agreement to continue their ground-breaking research at K2bio.

Key Points: 
  • HOUSTON, Dec. 21, 2021 /PRNewswire/ -- Ponce Therapeutics, founded by former Bellicum leaders Kevin Slawin and David Spencer, have signed an agreement to continue their ground-breaking research at K2bio.
  • We appreciate the variety of support services K2bio offers in addition to rental lab space," stated Kevin Slawin, CEO of Ponce Therapeutics.
  • "We are very excited to welcome Ponce Therapeutics to the K2bio family," said Kieron Jones, Co-founder, CEO, and President of K2bio.
  • About Ponce Therapeutics - Ponce Therapeutics is currently developing a biotechnology platform to restore young cells in the skin, targeting p16-expressing senescent cells for elimination.

Statera Biopharma Announces First Patient Dosed in Study of STAT-205 for Acute COVID

Retrieved on: 
Monday, December 20, 2021

FORT COLLINS, Colo., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today the enrollment and randomization of the first patient, with several more in screening for an initial study to evaluate STAT-205 as a potential treatment to mitigate SARS-CoV-2 progression, the virus that causes COVID-19. STAT-205 is an immune-modulator designed to decrease elevated inflammatory responses associated with cytokine production and modulate the Th1/Th2 helper cells to control immune dysfunction.

Key Points: 
  • Now that vaccines are widely available, developing safe and effective treatments for people who contract COVID-19 is our next challenge.
  • I am excited that our site has randomized the first patient in the clinical trial of STAT-205.
  • The study is designed to assess the pharmacokinetics (PK), early predictive biomarkers, and safety of STAT-205.
  • Statera has clinicalprograms for Crohns disease (STAT-201),hematology (Entolimod), pancreatic cancer (STAT-401) andCOVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.To learn more about Statera Biopharma, please visit www.staterabiopharma.com .

Nanjing Leads Biolabs and BeiGene Announce Worldwide License and Collaboration Agreement for LBL-007 Anti-LAG-3 Antibody; BeiGene Granted Exclusive Commercialization Rights Outside of China

Retrieved on: 
Tuesday, December 14, 2021

BeiGene is the ideal partner for Leads Biolabs given its extensive experience in the development of oncology medicines worldwide and the compelling immuno-oncology combination opportunity in its pipeline.

Key Points: 
  • BeiGene is the ideal partner for Leads Biolabs given its extensive experience in the development of oncology medicines worldwide and the compelling immuno-oncology combination opportunity in its pipeline.
  • By collaborating with BeiGene, Leads Biolabs expects to significantly accelerate the development and commercialization of LBL-007.
  • BeiGene has also entered into a collaboration with Novartis granting Novartis rights to develop, manufacture, and commercialize tislelizumab in North America, Europe, and Japan.
  • Nanjing Leads Biolabs (Leads Biolabs) is a clinical-stage US-Sino joint venture company, focusing on development and commercialization of second-generation immuno-oncology therapeutics.